ClinicalTrials.gg
RecruitingNCT07460180PROOVUpdated Mar 10, 2026

The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer

A Phase 1/2 interventional study of Olaparib in Ovarian Cancer, Epithelial Cancer and Fallopian Tube Cancer, sponsored by The Netherlands Cancer Institute. Recruiting at 1 site in Netherlands. Open to female participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by The Netherlands Cancer Institute · Phase 1/2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled May 2025, registered Nov 2025).
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 69 studies testing olaparib in Ovarian Neoplasms — 13 open to participants now, 26 under way, 9 of them phase 3. olaparib · Ovarian Neoplasms.

Planned enrollment
41st of 69
55 · median 96
Started
2025
with 3 others
Phase 1/2
2 of 69
1 open now
Primary completion
2027-05
later than 16 of 25 live
Registered
67th of 69
by date
Lead sponsor
2 of 69
The Netherlands Cancer Institute

Among the 69 studies testing olaparib in Ovarian Neoplasms, this one is the 41st largest by planned enrollment, is one of 4 that started in 2025, is one of 2 in phase 1/2, reaches primary completion later than 16 of the 25 other live ones, and was the 67th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

13 of the 69 studies testing olaparib in Ovarian Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 100 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing olaparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

The PROOV study is an open-label, monocenter, single-arm, prospective phase I/II trial with a safety lead-in, evaluating the feasibility of combining PARPi with HIPEC in stage III EOC patients. Phase I is a dose-finding phase with a time-to-event Bayesian Optimal Interval (TITE-BOIN) design, in which three doses of olaparib are evaluated to identify the optimal dose for the phase II part and future trials. The recommended phase II dose (RP2D) will be determined based on the experienced DLTs per dose level and the level of intra-tumor and systemic enzymatic PARP inhibition. During Phase II, the safety profile of the RP2D will be assessed in a total cohort of 40 patients. To provide a proof-of-concept, efficacy will be explored in both translational analyses and survival data.

Read the detailed description

Peritoneal recurrence is common in patients with advanced epithelial ovarian cancer (EOC) despite cytoreductive surgery (CRS) and platinum-based chemotherapy. Novel therapeutic strategies have emerged, such as Hyperthermic Intra PEritoneal Chemotherapy (HIPEC) added to interval CRS and maintenance therapy with poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors (PARPi). While these treatment strategies effectively delay recurrences, long-term survival for patients with advanced EOC remains poor.

It has been demonstrated that PARP inhibition synergizes with platinum compounds, but concurrent treatment with systemically administered platinum is considered too (myelo-)toxic. On the other hand, hyperthermia induces a transient state of homologous recombination deficiency (HRD) that is required for a therapeutic effect of PARP inhibition. Hence, we hypothesize that administering HIPEC when PARP is inhibited could optimally exploit the synergistic effect of local cisplatin and hyperthermia at the peritoneal surface without adding systemic toxicity.

The study population will consist of min. 40 to max. 55 patients with histologically proven FIGO stage III and operable stage IV high-grade serous ovarian cancer, peritoneal cancer, or fallopian tube carcinoma eligible for interval CRS with HIPEC, meaning that only patients with a response or stable disease after neo-adjuvant chemotherapy (NACT) will be eligible.

The study participants enrolled in the PROOV will receive seven days of PARPi (olaparib, Lynparza®) twice a day. The dosage will be either 100mg, 150mg or 300mg, depending on the phase of the trial. The treatment with olaparib will start 7 days before the scheduled CRS, with the final dose administered in the morning prior to the surgery. Following achievement of optimal or complete interval CRS, HIPEC will be performed by administering cisplatin intraperitoneally (either 100 mg/m2 with a maximum of 220 mg, or 40 mg/L) and sodium thiosulphate intravenously. Blood samples and peritoneal tissue samples (before and after HIPEC) will be collected for the translational analyses. Whenever possible, tissue at recurrence will also be collected.

03

Conditions studied

  • Ovarian Cancer
  • Epithelial Cancer
  • Fallopian Tube Cancer

Keywords

  • safety
  • efficacy
  • PARP inhibitor
  • HIPEC
  • Hyperthermic intraperitoneal Chemotherapy
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In order to be eligible to participate in this study, a subject must meet all of the following criteria:

    • Signed and written
    • At least 18 years of age and able to understand patients' information
    • FIGO stage III primary high-grade serous ovarian, fallopian tube, or extra-ovarian cancer.
    • FIGO stage IV is allowed in the following situations:

      • Resectable stage IV desease, such as local bowel involvement, iatrogenic abdominal wall or umbilical lesions
      • Stage IV based on cardiophrenic lymph nodes \<1cm
    • The diagnosis should be confirmed with either histology or cytology. If the diagnosis of ovarian carcinoma is based on cytology only, immunohistochemistry, including keratin 7, keratin 20, p53, PAX8 should be considered for confirmation of the diagnosis (at the discretion of the pathologist)
    • Eligible and planned for interval cytoreductive surgery with HIPEC

      • chemotherapy consists of at least 3 courses of carboplatin/paclitaxel
      • Patients should have response or stable disease after NACT; no progression should occur
      • Operability has been evaluated in a multidisciplinary team (MDT) meeting via CT scan, MRI or diagnostic laparoscopy and an optimal or complete interval CRS is deemed feasible
    • Fit for major surgery, 0-2
    • Adequate bone marrow function ( level >5.5 mmol/L, leukocytes >3 x10\^9/L, > 100 x10\^9/L)
    • Adequate hepatic function (, AST, and \< 2.5 times the )
    • Adequate renal function ( ≥ 60 ml/min using Cockcroft-Gault formula or 24-hour measurement or ml/min/1,73 m2 using or CKD-EPI)

Exclusion criteria

Exclusion Criteria:

  • A potential subject who meets any of the following criteria will be excluded from participation in this study:

    • History of previous treated with chemotherapy
    • Opting for fertility-sparing surgery
    • Concurrent use of potent inducers or inhibitors of as assessed with the KNMP "G-standaard" that cannot be stopped temporarily
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    PARPi (olaparib, Lynparza®)

    Drug: Olaparib

Interventions

  • seven days of PARPi (olaparib, Lynparza®) twice a day. The dosage will be either 100mg, 150mg or 300mg, depending on the phase of the trial.

06

What researchers measure

Primary outcomes

  1. Safety and toxicity of combining PARP-inhibitors with HIPEC

    Safety lead in phase 1 part: evaluation of dose limiting toxicities by CTCAE v.5 and Clavien dindo from start PARP inhibition until 28 days postoperatively. Evaluated dosages are 100mg, 150mg and 300mg BID of olaparib. Further toxicity will be evaluated in phase 2, in which an additional number of patients will be treated with recommended phase 2 dose.

    Time frame: 4 years

Secondary outcomes

  1. The degree of PARP (enzymatic) inhibition

    Blood and intracellular PARP activity will be measured, and the extent of PARP inhibition will be quantified as percentage reduction (%) from baseline activity levels in all enrolled patients.

    Time frame: 4 years

Other outcomes

  1. Overall survival (OS)

    Time frame: 10 years

  2. Recurrence-free survival (RFS)

    Time frame: 10 years

  3. Tumor cell proliferation (Ki67)

    Time frame: 4 years

  4. DNA damage (yH2AX foci assay)

    Time frame: 10 years

  5. ○ Apoptosis (cl-Casp3)

    Time frame: 4 years

  6. Functional homologous recombination (RAD51 foci assay)

    Time frame: 10 years

  7. The establishment of patient-derived organoids/explants cultures from tumor tissue collected intraoperatively

    Tumor tissue obtained during cytoreductive surgery will be used to generate PDOs and/or short-term explant cultures. These ex vivo models will be used to mimic the cellular response of patient tumors after clinical exposure to PARP inhibitors (PARPi) and HIPEC, allowing evaluation of treatment effects over time.

    Time frame: 4 years

  8. Treatment effects in the tumor microenvironment

    Spatial proteomics analyses (CODEX) comparing the baseline tumor microenvironment with the on post treatment tumor microenvironment.

    Time frame: 4 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.

Of 57 non-industry phase 1/2 interventional studies under Ovarian Neoplasms, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 110. This study's planned 24 months is below that.

Counting every sponsor, half of 173 studies reached it within 65 months; a quarter within 44 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2025
First posted
Mar 10, 2026
StartActual
May 1, 2025
Primary completionEst.
May 1, 2027
CompletionEst.
May 1, 2032
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07460180
Responsible party
Sponsor
First posted
Mar 10, 2026
Start date
May 1, 2025
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2032 (estimated)
Last update
Mar 10, 2026

Study contacts

madelief schreuder-goedheijt
Contact
m.schreudergoedheijt@nki.nl
0205129111
leah frenkel
Contact
l.frenkel@nki.nl
0205129111

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion